Effects of neoadjuvant chemical treatments in advanced ovarian cancer

Abstract

Introduction: In our country, 78% of ovarian cancer cases are diagnosed in stages III-IV, and the mortality rate is 4.4 cases per 100,000 female population. We aimed to investigate the efÏcacy of preoperative neoadjuvant chemotherapy in women diagnosed with late-stage ovarian epithelial cancer. Materials and Methods: The study was conducted from November 2020 to August 2021 based on the National Center for Cancer Research using a prospective longitudinal study model. Participants were followed for an average of 5±2 months until the end of neoadjuvant chemotherapy for ovarian epithelial cancer. Baseline assessments of all participants were collected on a questionnaire before chemotherapy, followed by chemotherapy, and re-evaluated for cancer markers and abdominal ascites after treatment. Results: The study included 33 women aged 30 to 70 years diagnosed with advanced ovarian epithelial cancer, with an average age of 54±9, all married, 33.3% (n=11) with primary education, 42.4% (n=14) overweight, and 15.2% (n=5) was obese. The mean tumor CA-125 marker decreased statistically to 1125.4±147.4 before treatment and to 63.9±14.8 after treatment (t=3.3, p=0.002). In the women diagnosed with advanced ovarian epithelial cancer, no deaths were reported within 28 days after surgery, and 84.8% (n=28) had complete removal of the tumor. Conclusion: 1. In women diagnosed with advanced ovarian cancer levels of CA125 U/ml markers, ascites before and after neoadjuvant chemotherapy were statistically significant. 2. Neoadjuvant chemotherapy has been shown to effectively inhibit the cancer process, reduce complications, and have a positive effect on the outcome of surgery.